ES2179385T3 - Preformulaciones homogeneas que contienen esteroides en alta concentracion, para la preparacion de composiciones farmaceuticas solidas y semisolidas debilmente dosificadas. - Google Patents
Preformulaciones homogeneas que contienen esteroides en alta concentracion, para la preparacion de composiciones farmaceuticas solidas y semisolidas debilmente dosificadas.Info
- Publication number
- ES2179385T3 ES2179385T3 ES97953625T ES97953625T ES2179385T3 ES 2179385 T3 ES2179385 T3 ES 2179385T3 ES 97953625 T ES97953625 T ES 97953625T ES 97953625 T ES97953625 T ES 97953625T ES 2179385 T3 ES2179385 T3 ES 2179385T3
- Authority
- ES
- Spain
- Prior art keywords
- steroid
- adjuvant
- solid
- preformulation
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LAS PREFORMULACIONES QUE CONTIENEN ESTEROIDES EN ELEVADA CONCENTRACION SON APROPIADAS PARA PREPARAR PREPARACIONES FARMACEUTICAS SOLIDAS Y SEMISOLIDAS CON BAJA DOSIFICACION CON UNA CONCENTRACION DE 0,001 A 1 % EN PESO DE ESTEROIDES. SE OBTIENEN MEDIANTE EVAPORACION DEL AGENTE DE DISPERSION QUE CONTIENE EL PRINCIPIO ACTIVO ESTEROIDAL A PARTIR DE UNA SUSPENSION QUE LLEVA ADYUVANTES USUALES FARMACEUTICOS, FORMANDOSE UNA NIEBLA DE PULVERIZACION, CUYO DIAMETRO MEDIO DE GOTA ES MAYOR QUE EL DIAMETRO MEDIO DE LAS PARTICULAS DE ADYUVANTE, Y EL MAXIMO TAMAÑO DE GRANO DE LAS PARTICULAS SECAS DE LA PREFORMULACION QUE LLEVAN ESTOS ESTEROIDES ESTA AUMENTADO EN MENOS DEL 30 %, EN RELACION CON EL TAMAÑO DE GRANO DEL ADYUVANTE. DICHAS PREFORMULACIONES SE CARACTERIZAN POR SU HOMOGENEIDAD Y RESISTENCIA A LA DISOCIACION, ESTANDO DISPERSADO FINAMENTE EL PRINCIPIO ACTIVO ESTEROIDAL Y UNIDO INTEGRAMENTE AL ADYUVANTE. SE DESCUBRIO SORPRESIVAMENTE QUE ESTOS TIPOS DE PREFORMULACIONES ESTEROIDALES, EN COMPARACION CONLOS PROCEDIMIENTOS CONVENCIONALES, SE PUEDEN PROCESAR SIN DIFICULTAD PARA OBTENER PREPARACIONES FARMACEUTICAS DE BAJA DOSIS CON MUY BUENA HOMOGENEIDAD Y BUENA ESTABILIDAD DEL PRINCIPIO ACTIVO. EL PROCEDIMIENTO PARA PRODUCIR FORMULACIONES ESTEROIDALES HOMOGENEAS PARA PREPARACIONES FARMACEUTICAS SOLIDAS Y SEMISOLIDAS DE BAJA DOSIS CON UNA CONCENTRACION DE ESTEROIDES DE ENTRE 0,01 Y 1 % EN PESO ES MEJOR ENTRE OTRAS COSAS POR EL HECHO DE QUE EL PRINCIPIO ACTIVO Y LAS PARTICULAS DE ADYUVANTE DE LA SOLUCION ATOMIZADA NO SE SECAN UNO AL LADO DEL OTRO. LA ELECCION DE LAS CONDICIONES DE PROCESADO DURANTE LA ATOMIZACION HACE POSIBLE PARA PRACTICAMENTE TODO EL PRINCIPIO ACTIVO QUE SE UNA INTEGRAMENTE AL ADYUVANTE.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19652196A DE19652196A1 (de) | 1996-12-16 | 1996-12-16 | Homogene steroidhaltige Präformulierungen zur Herstellung niedrigdosierter fester und halbfester pharmazeutischer Zubereitungen |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2179385T3 true ES2179385T3 (es) | 2003-01-16 |
Family
ID=7814809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES97953625T Expired - Lifetime ES2179385T3 (es) | 1996-12-16 | 1997-12-15 | Preformulaciones homogeneas que contienen esteroides en alta concentracion, para la preparacion de composiciones farmaceuticas solidas y semisolidas debilmente dosificadas. |
Country Status (13)
Country | Link |
---|---|
US (2) | US6290931B1 (es) |
EP (1) | EP0946149B1 (es) |
JP (1) | JP2001506639A (es) |
AT (1) | ATE219357T1 (es) |
AU (1) | AU5748098A (es) |
CA (1) | CA2275626C (es) |
CL (1) | CL2004000976A1 (es) |
DE (2) | DE19652196A1 (es) |
DK (1) | DK0946149T3 (es) |
ES (1) | ES2179385T3 (es) |
PT (1) | PT946149E (es) |
RU (1) | RU2178694C2 (es) |
WO (1) | WO1998026762A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19906152B4 (de) | 1999-02-10 | 2005-02-10 | Jenapharm Gmbh & Co. Kg | Wirkstoffhaltige Laminate für Transdermalsysteme |
JP2003527310A (ja) * | 1999-04-16 | 2003-09-16 | イエナフアルム ゲーエムベーハー ウント ツェーオー. カーゲー | エストロゲンを局部的に皮内投与するための医薬品組成物または化粧品組成物 |
US6787531B1 (en) * | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
EP1216713A1 (en) * | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions of estrogen-cyclodextrin complexes |
US20050220825A1 (en) * | 2004-03-10 | 2005-10-06 | Adrian Funke | Molecular dispersions of drospirenone |
DE102006026578B4 (de) | 2006-06-08 | 2009-01-08 | Lts Lohmann Therapie-Systeme Ag | Wirkstoffpartikelhaltiges Transdermales Therapeutisches System mit erhöhtem Wirkstofffluss und Verfahren zu seiner Herstellung sowie Verwendung |
DE102008037025C5 (de) | 2008-08-08 | 2016-07-07 | Jesalis Pharma Gmbh | Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4631284A (en) * | 1984-11-19 | 1986-12-23 | Mallinckrodt, Inc. | Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom |
IE67345B1 (en) | 1991-03-12 | 1996-03-20 | Akzo Nv | Low dose dry pharmaceutical preparations |
IT1252867B (it) * | 1991-12-31 | 1995-06-28 | Gentili Ist Spa | Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilita' |
DE69330672T2 (de) * | 1992-06-12 | 2002-06-27 | Teijin Ltd., Osaka | Pharmazeutische zubereitung zur anwendung in den atemwegen |
EP0611567B1 (en) * | 1992-06-12 | 2002-08-28 | Teijin Limited | Ultrafine powder for inhalation and production thereof |
US5395627A (en) * | 1992-09-04 | 1995-03-07 | Akzo N.V. | Pharmaceutical granulate |
DE4426709A1 (de) * | 1994-07-20 | 1996-01-25 | Schering Ag | Steroidale Sexualhormone enthaltende feste Arzneiformen |
-
1996
- 1996-12-16 DE DE19652196A patent/DE19652196A1/de not_active Withdrawn
-
1997
- 1997-12-15 US US09/319,802 patent/US6290931B1/en not_active Expired - Fee Related
- 1997-12-15 AU AU57480/98A patent/AU5748098A/en not_active Abandoned
- 1997-12-15 ES ES97953625T patent/ES2179385T3/es not_active Expired - Lifetime
- 1997-12-15 JP JP52718498A patent/JP2001506639A/ja active Pending
- 1997-12-15 RU RU99113041/14A patent/RU2178694C2/ru not_active IP Right Cessation
- 1997-12-15 WO PCT/DE1997/002915 patent/WO1998026762A1/de active IP Right Grant
- 1997-12-15 DE DE59707573T patent/DE59707573D1/de not_active Expired - Lifetime
- 1997-12-15 CA CA002275626A patent/CA2275626C/en not_active Expired - Fee Related
- 1997-12-15 EP EP97953625A patent/EP0946149B1/de not_active Expired - Lifetime
- 1997-12-15 PT PT97953625T patent/PT946149E/pt unknown
- 1997-12-15 AT AT97953625T patent/ATE219357T1/de not_active IP Right Cessation
- 1997-12-15 DK DK97953625T patent/DK0946149T3/da active
-
2001
- 2001-08-27 US US09/939,844 patent/US20020119103A1/en not_active Abandoned
-
2004
- 2004-05-07 CL CL200400976A patent/CL2004000976A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2001506639A (ja) | 2001-05-22 |
AU5748098A (en) | 1998-07-15 |
CL2004000976A1 (es) | 2005-01-21 |
EP0946149B1 (de) | 2002-06-19 |
EP0946149A1 (de) | 1999-10-06 |
DE19652196A1 (de) | 1998-06-18 |
CA2275626C (en) | 2005-02-15 |
US6290931B1 (en) | 2001-09-18 |
DE59707573D1 (de) | 2002-07-25 |
US20020119103A1 (en) | 2002-08-29 |
RU2178694C2 (ru) | 2002-01-27 |
DK0946149T3 (da) | 2002-10-07 |
WO1998026762A1 (de) | 1998-06-25 |
CA2275626A1 (en) | 1998-06-25 |
PT946149E (pt) | 2002-11-29 |
ATE219357T1 (de) | 2002-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chew et al. | Effect of amino acids on the dispersion of disodium cromoglycate powders | |
DE69812169T2 (de) | Mikropartikel und ihre therapeutische oder diagnostische verwendung | |
BR0317595A (pt) | Método e aparelho para produzir partìculas, método para produzir uma mistura de pó seco e composição farmacêutica | |
DK200000266A (da) | Farmaceutisk sammensætning indeholdende en opløsning af cyclosporin. | |
EP0167825A3 (en) | Lipid nano pellets as drug carriers for oral administration | |
DE3382587D1 (de) | Injizierbares langwirkendes mikroteilchen-praeparat zur verabreichung entzuendungshemmender mittel. | |
ATE232382T1 (de) | Pharmazeutische zusammensetzungen mit schneller freisetzung von wirkstoffen | |
HUP0300593A2 (hu) | Kemény pelletként kialakított gyógyászati készítmény száraz porral mżködż inhalátorhoz | |
JPH0687758A (ja) | Lhrhホルモンおよびその類似体を徐々に放出する微小球体の製造方法と、その微小球体と、それを含む製剤 | |
AU3426400A (en) | Modified carrier particles for use in dry powder inhalers | |
Momin et al. | Manipulation of spray-drying conditions to develop dry powder particles with surfaces enriched in hydrophobic material to achieve high aerosolization of a hygroscopic drug | |
CA2139424A1 (en) | Fabric Conditioning Compositions and Process for Making Them | |
ES2179385T3 (es) | Preformulaciones homogeneas que contienen esteroides en alta concentracion, para la preparacion de composiciones farmaceuticas solidas y semisolidas debilmente dosificadas. | |
Fults et al. | Effect of particle morphology on emitted dose of fatty acid-treated disodium cromoglycate powder aerosols | |
Tewa-Tagne et al. | Spray-drying nanocapsules in presence of colloidal silica as drying auxiliary agent: formulation and process variables optimization using experimental designs | |
DE60137452D1 (de) | Pulverzubereitungen und verfahren zu ihrer herstellung | |
CN1972668B (zh) | 含三萜的成油凝胶剂、含三萜的油凝胶和制备含三萜的油凝胶的方法 | |
Wiessner et al. | Effect of particle size on quartz-induced hemolysis and on lung inflammation and fibrosis | |
Philip et al. | Effect of surface treatment on the respirable fractions of PLGA microspheres formulated for dry powder inhalers | |
JPH11130659A (ja) | 水性懸濁医薬品組成物 | |
BR9902778A (pt) | Composições de suspensão em pó com componentes de resina de carbamato particulado sólido disperso em carreador de resina de aminoplasto lìquida | |
US3600326A (en) | Preparation of hydrophobic silica and use thereof | |
US5021554A (en) | Process for protein particle size reduction using a fluid-energy mill | |
Guo et al. | Investigation of the release of aspirin from spray-congealed micro-pellets | |
Zahn et al. | Species-specific aggregation factor in sponges. I. Characterization of the large circular proteid particle |